{"nct_id":"NCT03725059","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-07","start_date":"2018-12-27","start_date_type":"ACTUAL","primary_completion_date":"2031-01-24","primary_completion_date_type":"ESTIMATED","completion_date":"2031-01-24","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}